MELANOMA is a particularly aggressive form of skin cancer that resists
conventional treatments. But a new drug could make it vulnerable to chemotherapy
by throwing a DNA spanner into its defensive works.
In the first clinical trial of the drug, called G3139, 43 per cent of the 14
patients saw a measurable shrinkage in their tumours after treatment, says
Burkhard Jansen of Vienna University. One patient has been in complete remission
for almost two months.
“I am excited about this. But I’m waiting,” says Donald Coffey of Johns
Hopkins University, cautioning that the Austrian trial involved only a small
number…
